DelveInsight’s report titled “Friedreich Ataxia Pipeline Insight 2023” offers extensive information on more than 10+ companies and over 10+ pipeline drugs in the field of Friedreich Ataxia research. The Friedreich Ataxia pipeline report encompasses detailed profiles of the pipeline drugs for Friedreich Ataxia, including information on Friedreich Ataxia clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.

 

For the Friedreich Ataxia emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Friedreich Ataxia pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Friedreich Ataxia clinical trial studies conducted for Friedreich Ataxia, any NDA approvals obtained for Friedreich Ataxia, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.

 

To explore more information on the latest breakthroughs in the Friedreich Ataxia Pipeline treatment landscape of the report, click here @ Friedreich Ataxia Pipeline Outlook

 

Key Takeaways from the Friedreich Ataxia Pipeline Report

• DelveInsight’s Friedreich Ataxia Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading Friedreich Ataxia Companies are working in the market include PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics, and others
• Promising Friedreich Ataxia Pipeline Therapies in the various stages of development include RT001, Idebenone, interferon γ-1b, Idebenone, RT 001, Leriglitazone, and others
• RT001 is a clinical-stage isotopically stabilized, synthetic linoleic acid (LA) discovered and developed with Retrotope’s novel platform technology. This platform is designed to combat the oxidative stress and cellular degeneration that arises from lipid peroxidation (LPO). It is currently in phase III stage of development for Friedreich’s ataxia and is being developed by Retrotope.
• Leriglitazone (MIN-102) is a novel, orally bioavailable and selective PPAR gamma agonist with a potential best-in-class profile indicated for CNS diseases. It is one of the several metabolites of pioglitazone and has a demonstrated sufficient brain penetration and favorable safety profile in humans, allowing PPAR gamma engagement in the CNS above the level that can be safely achieved with pioglitazone and other glitazones. It showed robust preclinical proof-of-concept in animal models of multiple diseases by modulating pathways leading to mitochondrial dysfunction, oxidative stress, neuroinflammation, demyelination and axonal degeneration. It is currently in phase II stage of development and is being developed by Minoryx Therapeutics.

 

Friedreich Ataxia Overview

Friedreich’s Ataxia (FRDA) is a genetic, progressive, neurodegenerative movement disorder, with a typical age of onset between 10 and 15 years. Initial symptoms may include unsteady posture, frequent falling, and progressive difficulty in walking due to impaired ability to coordinate voluntary movements (ataxia). Affected individuals often develop slurred speech (dysarthria), characteristic foot deformities, and an irregular curvature of the spine (scoliosis).

 

For further information, refer to the detailed Friedreich Ataxia Unmet Needs, Friedreich Ataxia Market Drivers, and Market Barriers, click here for Friedreich Ataxia Ongoing Clinical Trial Analysis

 

Friedreich Ataxia Emerging Drugs Profile

• RT 001: Retrotope
• Leriglitazone: Minoryx Therapeutics

 

Friedreich Ataxia Pipeline Therapeutics Assessment

There are approx. 10+ Friedreich Ataxia companies which are developing the Friedreich’s Ataxia. The Friedreich Ataxia companies which have their Friedreich’s Ataxia drug candidates in the most advanced stage, i.e. Phase III include, Retrotope.

 

Request a sample and discover the recent advances in Friedreich Ataxia Ongoing Clinical Trial Analysis and Medications, click here @ Friedreich Ataxia Treatment Landscape

 

Friedreich Ataxia Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Friedreich Ataxia Therapeutics Market include-

PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics, and others.

 

Dive deep into rich insights for drugs for Friedreich Ataxia Pipeline, click here @ Friedreich Ataxia Unmet Needs and Analyst Views

 

Scope of the Friedreich Ataxia Pipeline Report

• Coverage- Global
• Friedreich Ataxia Companies- PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics, and others.
• Friedreich Ataxia Pipeline Therapies- RT001, Idebenone, interferon γ-1b, Idebenone, RT 001, Leriglitazone, and others
• Friedreich Ataxia Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Friedreich Ataxia Mergers and acquisitions, Friedreich Ataxia Licensing Activities @ Friedreich Ataxia Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Friedreich Ataxia Executive Summary
3. Friedreich’s Ataxia: Overview
4. Friedreich Ataxia Pipeline Therapeutics
5. Friedreich Ataxia Therapeutic Assessment
6. Friedreich’s Ataxia– DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Friedreich’s Ataxia Collaboration Deals
9. Late Stage Products (Phase III)
10. RT 001: Retrotope
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Leriglitazone: Minoryx Therapeutics
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. CTI-1601: Larimar Therapeutics
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. LX-2006: LEXEO Therapeutics
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Friedreich’s Ataxia Key Companies
23. Friedreich’s Ataxia Key Products
24. Friedreich’s Ataxia- Unmet Needs
25. Friedreich’s Ataxia- Market Drivers and Barriers
26. Friedreich’s Ataxia- Future Perspectives and Conclusion
27. Friedreich’s Ataxia Analyst Views
28. Friedreich’s Ataxia Key Companies
29. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services